Biomarkers
Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
Journal of Experimental & Clinical Cancer Research 2022 August 20 [Link] Paola Muti, Andrea Sacconi, Claudio Pulito, Giulia Orlandi, Sara Donzelli, Aldo Morrone, James Jiulian, Gerard P Cox, Martin Kolb, Gregory Pond, Peter Kavsak, Mark Norman Levine, Giovanni Blandino, Sabrina Strano Abstract Background: Malignant pleural mesothelioma is a highly aggressive tumor associated with asbestos exposure.…
Read MoreDiagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma
Journal of the American Society of Cytopathology 2022 July 9 [Link] Louise Andersen Lynggård, Vasiliki Panou, Weronika Szejniuk, Oluf Dimitri Røe, Christos Meristoudis Abstract Introduction: Serous effusion is often the first sign of mesothelioma. Diagnosis based on cytologic material from the effusions remains controversial and complementary biopsy is usually required. However, obtaining representative tissue sample…
Read MoreMolecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
Targeted Oncology 2022 July 30 [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos…
Read MoreNFE2L3 as a Novel Biomarker Associated With IL-2/STAT5/NLRP3 Signaling Pathway in Malignant Pleural Mesothelioma and Other Cancers
Frontiers in Genetics 2022 May 18 [Link] Zhen Wang, Han Yang, Bin Luo, Pengfei Duan, Peng Lin Abstract Background: Malignant pleural mesothelioma (MPM) is a malignant tumor originating from pleural mesothelial cells and has a high mortality rate worldwide. With the advent of immunotherapy in MPM treatment, there is an urgent need to elucidate the…
Read MoreDysregulation of microRNAs and tRNA-derived ncRNAs in mesothelial and mesothelioma cell lines after asbestiform fiber exposure
Scientific Reports 2022 June 2 [Link] Veronica Filetti, Alessandro La Ferlita, Antonio Di Maria, Venera Cardile, Adriana C E Graziano, Venerando Rapisarda, Caterina Ledda, Alfredo Pulvirenti, Carla Loreto Abstract Experimental evidence demonstrated that fluoro-edenite (FE) can develop chronic respiratory diseases and elicit carcinogenic effects. Environmental exposure to FE fibers is correlated with malignant pleural mesothelioma…
Read MoreEpithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study
International Journal of Molecular Sciences 2022 May 21 [Link] Laura Mannarino, Lara Paracchini, Federica Pezzuto, Gheorghe Emilian Olteanu, Laura Moracci, Luca Vedovelli, Irene De Simone, Cristina Bosetti, Monica Lupi, Rosy Amodeo, Alessia Inglesi, Maurizio Callari, Serena Penpa, Roberta Libener, Sara Delfanti, Antonina De Angelis, Alberto Muzio, Paolo Andrea Zucali, Paola Allavena, Giovanni Luca Ceresoli, Sergio…
Read MoreHeadspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research
Frontiers in Oncology 2022 May 6 [Link] Eline Janssens, Zoë Mol, Lore Vandermeersch, Sabrina Lagniau, Karim Y Vermaelen, Jan P van Meerbeeck, Christophe Walgraeve, Elly Marcq, Kevin Lamote Abstract Introduction: Malignant pleural mesothelioma (MPM) is a lethal cancer for which early-stage diagnosis remains a major challenge. Volatile organic compounds (VOCs) in breath proved to be…
Read MoreEZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
The Lancet Oncology 2022 May 16 [Link] Marjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, Sanjay Popat, Paul Taylor, David Planchard, Arnaud Scherpereel, Marianna Koczywas, Martin Forster, Robert B Cameron, Tobias Peikert, Evren Kocabaş Argon, Neil R Michaud, Attila Szanto, Jay Yang, Yingxue Chen, Vikram Kansra, Shefali Agarwal, Dean A Fennell Abstract Background: Treatment…
Read More5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies
Virchows Archiv 2022 May 16 [Link] Ziyad Alsugair, Vahan Kepenekian, Tanguy Fenouil, Olivier Glehen, Laurent Villeneuve, Sylvie Isaac, Juliette Hommell-Fontaine, Nazim Benzerdjeb Abstract The differentiation between reactive mesothelial hyperplasia (RMH) and diffuse malignant peritoneal mesothelioma (DMPM) is challenging especially when applied on peritoneal small samples. The use of BRCA-associated protein 1 (BAP1) and methylthioadenosine phosphorylase…
Read MoreGeneration and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Journal of Visualized Experiments 2022 April 21 [Link] Tamara M Griffiths, Carlos Ramos, Cara L Haymaker Abstract Current methodologies for the expansion of primary tumor cell lines from rare tumor types are lacking. This protocol describes methods to expand primary tumor cells from surgically resected, malignant pleural mesothelioma (MPM) by providing a complete overview of…
Read More